Preclinical and clinical development of siRNA-based therapeutics

Advanced Drug Delivery Reviews

Volumn 87, Issue , 2015, Pages 108-119

  Ozcan, Gulnihal ^a   Ozpolat, Bulent ^a   Coleman, Robert L ^a   Sood, Anil K ^a   Lopez Berestein, Gabriel ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

EphA2; Gene silencing; Nanocarriers; Nanoliposomes; Ovarian cancer; SiRNA; Therapeutic use

Indexed keywords

CHEMICAL MODIFICATION; GENES; MAMMALS; RNA;

EPHA2; GENE SILENCING; NANO-CARRIERS; NANOLIPOSOMES; OVARIAN CANCERS; SIRNA; THERAPEUTIC USE;

DISEASES;

AGN 211745; ALN AT3SC; ALN PCS02; ALN PCSSC; ALN TTR01; ALN VSP02; APN 401; ASVASIRAN; ATU 027; BAMOSIRAN; BEVASIRANIB; CALAA 01; DCR MYC; DIOLEOYLPHOSPHATIDYLCHOLINE; EPHRIN RECEPTOR A2; NANOCARRIER; ND L02 S0201; PATISIRAN; PF 04523655; PRO 040201; QPI 1002; QPI 1007; REVUSIRAN; SIG12D; SMALL INTERFERING RNA; SYL 1001; TD 101; TKM 080301; TKM 100201; UNCLASSIFIED DRUG; UNINDEXED DRUG; DRUG CARRIER; NANOPARTICLE;

ACUTE KIDNEY FAILURE; ADRENAL CORTEX CARCINOMA; AGE RELATED MACULAR DEGENERATION; ALGORITHM; AMYLOIDOSIS; ANTERIOR ISCHEMIC OPTIC NEUROPATHY; CHEMICAL MODIFICATION; CLOSED ANGLE GLAUCOMA; COMPUTER MODEL; CONGENITAL PACHYONYCHIA; DIABETIC MACULAR EDEMA; DIABETIC RETINOPATHY; DRUG DELIVERY SYSTEM; DRUG DESIGN; DRUG TARGETING; DRY EYE; EBOLA HEMORRHAGIC FEVER; EYE PAIN; GENE SILENCING; HEART AMYLOIDOSIS; HEMOPHILIA A; HEMOPHILIA B; HUMAN; HYPERCHOLESTEROLEMIA; INJECTION SITE PAIN; INTRAOCULAR HYPERTENSION; KIDNEY CANCER; KIDNEY INJURY; LIVER CELL CARCINOMA; LIVER FIBROSIS; LIVER TUMOR; MACULAR DEGENERATION; MELANOMA; MULTICENTER STUDY (TOPIC); MULTIPLE MYELOMA; NEUROENDOCRINE TUMOR; NONHODGKIN LYMPHOMA; NONHUMAN; OPEN ANGLE GLAUCOMA; OPTIC NERVE ATROPHY; OVARY CANCER; PANCREAS ADENOCARCINOMA; PANCREAS CANCER; PANCREAS CARCINOMA; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RESPIRATORY SYNCYTIAL VIRUS INFECTION; REVIEW; RNA INTERFERENCE; SOLID TUMOR; SUBRETINAL NEOVASCULARIZATION; ANIMAL; CHEMISTRY; CLINICAL TRIAL (TOPIC); DRUG EFFECTS; FEMALE; GENE TARGETING; GENETICS; OVARIAN NEOPLASMS; PRECLINICAL STUDY;

ANIMALS; CLINICAL TRIALS AS TOPIC; DRUG CARRIERS; DRUG DESIGN; DRUG EVALUATION, PRECLINICAL; FEMALE; GENE TARGETING; HUMANS; NANOPARTICLES; OVARIAN NEOPLASMS; RECEPTOR, EPHA2; RNA INTERFERENCE; RNA, SMALL INTERFERING;

EID: 84937250536     PISSN: 0169409X     EISSN: 18728294     Source Type: Journal    
DOI: 10.1016/j.addr.2015.01.007     Document Type: Review

References (122)

1. Jorgensen R. Altered gene expression in plants due to transinteractions between homologous genes. Trends Biotechnol. 1990, 8(12):340-344.
2. Fire A., Xu S., Montgomery M.K., Kostas S.A., Driver S.E., Mello C.C. Potent and specific genetic interference by double-stranded RNA in Caenorhabditis elegans. Nature 1998, 391:806-811.
3. Elbashir S.M., Harborth J., Lendeckel W., Yalcin A., Weber K., Tuschl T. Duplexes of 21-nucleotide RNAs mediate RNA interference in cultured mammalian cells. Nature 2001, 24(411):494-498.
4. Kaikkonen M.U., Lam M.T., Glass C.K. Non-coding RNAs as regulators of gene expression and epigenetics. Cardiovasc. Res. 2011, 90(3):430-440.
5. Batista P.J., Chang H.Y. Long noncoding RNAs: cellular address codes in development and disease. Cell 2013, 152(6):1298-1307.
6. Sana J., Faltejskova P., Svoboda M., Slaby O. Novel classes of non-coding RNAs and cancer. J. Transl. Med. 2012, 10:103.
7. Hammond S.M., Caudy A.A., Hannon G.J. Post-transcriptional gene silencing by double-stranded RNA. Nat. Rev. Genet. 2001, 2(2):110-119.
8. He L., Hannon G.J. MicroRNAs: small RNAs with a big role in gene regulation. Nat. Rev. Genet. 2004, 5(7):522-531.
9. Meister G., Tuschl T. Mechanisms of gene silencing by double-stranded RNA. Nature 2004, 431:343-349.
10. Siomi H., Siomi M.C. On the road to reading the RNA-interference code. Nature 2009, 457:396-404.
11. de Fougerolles A., Vornlocher H.P., Maraganore J., Lieberman J. Interfering with disease: a progress report on siRNA-based therapeutics. Nat. Rev. Drug Discov. 2007, 6(6):443-453.
12. Kim D.H., Rossi J.J. Strategies for silencing human disease using RNA interference. Nat. Rev. Genet. 2007, 8(3):173-184.
13. Pecot C.V., Calin G.A., Coleman R.L., Lopez-Berestein G., Sood A.K. RNA interference in the clinic: challenges and future directions. Nat. Rev. Cancer 2011, 11(1):59-67.
14. Snøve O., Holen T. Many commonly used siRNAs risk off-target activity. Biochem. Biophys. Res. Commun. 2004, 319(1):256-263.
15. Doench J.G., Petersen C.P., Sharp P.A. siRNAs can function as miRNAs. Genes Dev. 2003, 17:438-442.
16. Jackson A.L., Burchard J., Schelter J., Chau B.N., Cleary M., Lim L., Linsley P.S. Widespread siRNA "off-target" transcript silencing mediated by seed region sequence complementarity. RNA 2006, 12(7):1179-1187.
17. Yiu S.M., Wong P.W., Lam T.W., Mui Y.C., Kung H.F., Lin M., Cheung Y.T. Filtering of ineffective siRNAs and improved siRNA design tool. Bioinformatics 2005, 21(2):144-151.
18. Naito Y., Ui-Tei K. Designing functional siRNA with reduced off-target effects. Methods Mol. Biol. 2013, 942:57-68.
19. Chalk A.M., Wahlestedt C., Sonnhammer E.L. Improved and automated prediction of effective siRNA. Biochem. Biophys. Res. Commun. 2004, 319(1):264-274.
20. Juliano R., Alam M.R., Dixit V., Kang H. Mechanisms and strategies for effective delivery of antisense and siRNA oligonucleotides. Nucleic Acids Res. 2008, 36(12):4158-4171.
21. Bartlett D.W., Davis M.E. Effect of siRNA nuclease stability on the in vitro and in vivo kinetics of siRNA-mediated gene silencing. Biotechnol. Bioeng. 2007, 97(4):909-921.
22. Volkov A.A., Kruglova N.S., Meschaninova M.I., Venyaminova A.G., Zenkova M.A., Vlassov V.V., Chernolovskaya E.L. Selective protection of nuclease-sensitive sites in siRNA prolongs silencing effect. Oligonucleotides 2009, 19(2):191-202.
23. Behlke M.A. Chemical modification of siRNAs for in vivo use. Oligonucleotides 2008, 18(4):305-319.
24. Braasch D.A., Paroo Z., Constantinescu A., Ren G., Oz O.K., Mason R.P., Corey D.R. Biodistribution of phosphodiester and phosphorothioate siRNA. Bioorg. Med. Chem. Lett. 2004, 14:1139-1143.
25. Soutschek J., Akinc A., Bramlage B., Charisse K., Constien R., Donoghue M., Elbashir S., Geick A., Hadwiger P., Harborth J., John M., Kesavan V., Lavine G., Pandey R.K., Racie T., Rajeev K.G., Rohl I., Toudjarska I., Wang G., Wuschko S., Bumcrot D., Koteliansky V., Limmer S., Manoharan M., Vornlocher H.P. Therapeutic silencing of an endogenous gene by systemic administration of modified siRNAs. Nature 2004, 432:173-178.
26. Ozpolat B., Sood A.K., Lopez-Berestein G. Nanomedicine based approaches for the delivery of siRNA in cancer. J. Intern. Med. 2010, 267(1):44-53.
27. Wang J., Lu Z., Wientjes M.G., Au J.L. Delivery of siRNA therapeutics: barriers and carriers. AAPS J. 2010, 12(4):492-503.
28. Sioud M. Deciphering the code of innate immunity recognition of siRNAs. Methods Mol. Biol. 2009, 487:41-59.
29. Judge A.D., Sood V., Shaw J.R., Fang D., McClintock K., MacLachlan I. Sequence-dependent stimulation of the mammalian innate immune response by synthetic siRNA. Nat. Biotechnol. 2005, 23(4):457-462.
30. Hornung V., Guenthner-Biller M., Bourquin C., Ablasser A., Schlee M., Uematsu S., Noronha A., Manoharan M., Akira S., de Fougerolles A., Endres S., Hartmann G. Sequence-specific potent induction of IFN-alpha by short interfering RNA in plasmacytoid dendritic cells through TLR7. Nat. Med. 2005, 11(3):263-270.
31. Sioud M. Does the understanding of immune activation by RNA predict the design of safe siRNAs?. Front. Biosci. 2008, 13:4379-4392.
32. Fedorov Y., Anderson E.M., Birmingham A., Reynolds A., Karpilow J., Robinson K., Leake D., Marshall W.S., Khvorova A. Off-target effects by siRNA can induce toxic phenotype. RNA 2006, 12(7):1188-1196.
33. Sioud M., Leirdal M. Potential design rules and enzymatic synthesis of siRNAs. Methods Mol. Biol. 2004, 252:457-469.
34. Jagla B., Aulner N., Kelly P.D., Song D., Volchuk A., Zatorski A., Shum D., Mayer T., De Angelis D.A., Ouerfelli O., Rutishauser U., Rothman J.E. Sequence characteristics of functional siRNAs. RNA 2005, 11(6):864-872.
35. Takasaki S. Methods for selecting effective siRNA sequences by using statistical and clustering techniques. Methods Mol. Biol. 2009, 487:1-39.
36. Walton S.P., Wu M., Gredell J.A., Chan C. Designing highly active siRNAs for therapeutic applications. FEBS J. 2010, 277(23):4806-4813.
37. Yuan B., Latek R., Hossbach M., Tuschl T., Lewitter F. siRNA Selection Server: an automated siRNA oligonucleotide prediction server. Nucleic Acids Res. 2004, 32:W130-W134.
38. Hajeri P.B., Singh S.K. siRNAs: their potential as therapeutic agents-part I. Designing of siRNAs. Drug Discov. Today 2009, 17-18:851-858.
39. Dawson L.A., Usmani B.A. Design, manufacture, and assay of the efficacy of siRNAs for gene silencing. Methods Mol. Biol. 2008, 439:403-419.
40. Wang X., Wang X., Varma R.K., Beauchamp L., Magdaleno S., Sendera T.J. Selection of hyperfunctional siRNAs with improved potency and specificity. Nucleic Acids Res. 2009, 37(22):e152.
41. Snøve O., Nedland M., Fjeldstad S.H., Humberset H., Birkeland O.R., Grünfeld T., Saetrom P. Designing effective siRNAs with off-target control. Biochem. Biophys. Res. Commun. 2004, 325(3):769-773.
42. Hannus M., Beitzinger M., Engelmann J.C., Weickert M.T., Spang R., Hannus S., Meister G. siPools: highly complex but accurately defined siRNA pools eliminate off-target effects. Nucleic Acids Res. 2014, 42(12):8049-8061.
43. Czauderna F., Fechtner M., Dames S., Aygun H., Klippel A., Pronk G.J., Giese K., Kaufmann J. Structural variations and stabilising modifications of synthetic siRNAs in mammalian cells. Nucleic Acids Res. 2003, 31:2705-2716.
44. Choung S., Kim Y.J., Kim S., Park H.O., Choi Y.C. Chemical modification of siRNAs to improve serum stability without loss of efficacy. Biochem. Biophys. Res. Commun. 2006, 342:919-927.
45. Richardson F.C., Tennant B.C., Meyer D.J., Richardson K.A., Mann P.C., Mcginty G.R., Wolf J.L., Zack P.M., Bendele R.A. An evaluation of the toxicities of 2'-fluorouridine and 2'-fluorocytidine-HCl in F344 rats and woodchucks. Toxicol. Pathol. 1999, 27:607-617.
46. Richardson F.C., Zhang C., Lehrman S.R., Koc H., Swenberg J.A., Richardson K.A., Bendele R.A. Quantification of 2'-fluoro-2'-deoxyuridine and 2'-fluoro-2'-deoxycytidine in DNA and RNA isolated from rats and woodchucks using LC/MS/MS. Chem. Res. Toxicol. 2002, 15:922-926.
47. Wu S.Y., Yang X., Gharpure K.M., Hatakeyama H., Egli M., McGuire M.H., Nagaraja A.S., Miyake T.M., Rupaimoole R., Pecot C.V., Taylor M., Pradeep S., Sierant M., Rodriguez-Aguayo C., Choi H.J., Previs R.A., Armaiz-Pena G.N., Huang L., Martinez C., Hassell T., Ivan C., Sehgal V., Singhania R., Han H.D., Su C., Kim J.H., Dalton H.J., Kovvali C., Keyomarsi K., McMillan N.A., Overwijk W.W., Liu J., Lee J.S., Baggerly K.A., Lopez-Berestein G., Ram P.T., Nawrot B., Sood A.K. 2'-OMe-phosphorodithioate-modified siRNAs show increased loading into the RISC complex and enhanced anti-tumour activity. Nat. Commun. 2014, 5:3459.
48. Fluiter K., Ten Asbroek A.L., De Wissel M.B., Jakobs M.E., Wissenbach M., Olsson H., Olsen O., Oerum H., Baas F. In vivo tumor growth inhibition and biodistribution studies of locked nucleic acid (LNA) antisense oligonucleotides. Nucleic Acids Res. 2003, 31:953-962.
49. Swayze E.E., Siwkowski A.M., Wancewciz E.V., Migawa M.T., Wyrzykiewicz T.K., Hung G., Monia B.P., Bennett C.F. Antisense oligonucleotides containing locked nucleic acid improve potency but cause significant hepatotoxicity in animals. Nucleic Acids Res. 2007, 35:687-700.
50. Zou Y., Tiller P., Chen I.W., Beverly M., Hochman J. Metabolite identification of small interfering RNA duplex by high-resolution accurate mass spectrometry. Rapid Commun. Mass Spectrom. 2008, 22:1871-1881.
51. Hogrefe R.I., Lebedev A.V., Zon G., Pirollo K.F., Rait A., Zhou Q., Yu W., Chang E.H. Chemically modified short interfering hybrids (siHYBRIDS): nanoimmunoliposome delivery in vitro and in vivo for RNAi of HER-2. Nucleosides Nucleotides Nucleic Acids 2006, 25:889-907.
52. Pirollo K.F., Rait A., Zhou Q., Hwang S.H., Dagata J.A., Zon G., Hogrefe R.I., Palchik G., Chang E.H. Materializing the potential of small interfering RNA via a tumor targeting nanodelivery system. Cancer Res. 2007, 67:2938-2943.
53. Ui-Tei K., Naito Y., Zenno S., Nishi K., Yamato K., Takahashi F., Juni A., Saigo K. Functional dissection of siRNA sequence by systematic DNA substitution: modified siRNA with a DNA seed arm is a powerful tool for mammalian gene silencing with significantly reduced off-target effect. Nucleic Acids Res. 2008, 36(7):2136-2151.
54. Jackson A.L., Burchard J., Leake D., Reynolds A., Schelter J., Guo J., Johnson J.M., Lim L., Karpilow J., Nichols K., Marshall W., Khvorova A., Linsley P.S. Position-specific chemical modification of siRNAs reduces "off-target" transcript silencing. RNA 2006, 12:1197-1205.
55. Puri N., Wang X., Varma R., Burnett C., Beauchamp L., Batten D.M., Young M., Sule V., Latham K., Sendera T., Echeverri C., Sachse C., Magdaleno S. LNA incorporated siRNAs exhibit lower off-target effects compared to 2'-OMethoxy in cell phenotypic assays and microarray analysis. Nucleic Acids Symp. Ser. (Oxf). 2008, 52:25-26.
56. Chen P.Y., Weinmann L., Gaidatzis D., Pei Y., Zavolan M., Tuschl T., Meister G. Strand-specific 50-O-methylation of siRNA duplexes controls guide strand selection and targeting specificity. RNA 2008, 14:263-274.
57. Bramsen J.B., Laursen M.B., Damgaard C.K., Lena S.W., Babu B.R., Wengel J., Kjems J. Improved silencing properties using small internally segmented interfering RNAs. Nucleic Acids Res. 2007, 35(17):5886-5897.
58. Sioud M., Furset G., Cekaite L. Suppression of immunostimulatory siRNA-driven innate immune activation by 2'-modified RNAs. Biochem. Biophys. Res. Commun. 2007, 361:122-126.
59. Jackson A.L., Linsley P.S. Recognizing and avoiding siRNA off-target effects for target identification and therapeutic application. Nat. Rev. Drug Discov. 2010, 9(1):57-67.
60. Ozpolat B., Sood A.K., Lopez-Berestein G. Liposomal siRNA nanocarriers for cancer therapy. Adv. Drug Deliv. Rev. 2014, 66:110-116.
61. Zhou J., Shum K.T., Burnett J.C., Rossi J.J. Nanoparticle-based delivery of RNAi therapeutics: progress and challenges. Pharmaceuticals (Basel) 2013, 6(1):85-107.
62. Minakuchi Y., Takeshita F., Kosaka N., Sasaki H., Yamamoto Y., Kouno M., Honma K., Nagahara S., Hanai K., Sano A., et al. Atelocollagen-mediated synthetic siRNA delivery for effective gene silencing in vitro and in vivo. Nucleic Acids Res. 2004, 32:e109.
63. Tan W.B., Jiang S., Zhang Y. Quantum-dot based nanoparticles for targeted silencing of HER2/neu gene via RNA interference. Biomaterials 2007, 28(8):1565-1571.
64. Lee J.H., Lee K., Moon S.H., Lee Y., Park T.G., Cheon J. All-in-one target-cell-specific magnetic nanoparticles for simultaneous molecular imaging and siRNA delivery. Angew. Chem. Int. Ed. Engl. 2009, 48(23):4174-4179.
65. Yu D., Peng P., Dharap S.S., Wang Y., Mehlig M., Chandna P., et al. Antitumor activity of poly(ethylene glycol)-camptothecin conjugate: the inhibition of tumor growth in vivo. J. Control. Release 2005, 110:90-102.
66. Dokka S., Toledo D., Shi X., Castranova V., Rojanasakul Y. Oxygen radical-mediated pulmonary toxicity induced by some cationic liposomes. Pharm. Res. 2000, 17(5):521.
67. Spagnou S., Miller A.D., Keller M. Lipid carriers of siRNA: differences in the formulation, cellular uptake, and delivery with plasmid DNA. Biochemistry 2004, 43:13348-13356.
68. Lv H., Zhang S., Wang B., Cui S., Yan J. Toxicity of cationic lipids and cationic polymers in gene delivery. J. Control. Release 2006, 114:100-109.
69. Landen C.N., Chavez-Reyes A., Bucana C., Schmandt R., Deavers M.T., Lopez-Berestein G., Sood A.K. Therapeutic EphA2 gene targeting in vivo using neutral liposomal small interfering RNA delivery. Cancer Res. 2005, 65:6910-6918.
70. Halder J., Kamat A.A., Landen C.N., Han L.Y., Lutgendorf S.K., Lin Y.G., Merritt W.M., Jennings N.B., Chavez-Reyes A., Coleman R.L., Gershenson D.M., Schmandt R., Cole S.W., Lopez-Berestein G., Sood A.K. Focal adhesion kinase targeting using in vivo short interfering RNA delivery in neutral liposomes for ovarian carcinoma therapy. Clin. Cancer Res. 2006, 12:4916-4924.
71. Gray M.J., Van Buren G., Dallas N.A., Xia L., Wang X., Yang A.D., Somcio R.J., Lin Y.G., Lim S., Fan F., Mangala L.S., Arumugam T., Logsdon C.D., Lopez-Berestein G., Sood A.K., Ellis L.M. Therapeutic targeting of neuropilin-2 on colorectal carcinoma cells implanted in the murine liver. J. Natl. Cancer Inst. 2008, 100:109-120.
72. Shao L.J., Tekedereli I., Wang J., Yuca E., Tsang S., Sood A.K., Lopez-Berestein G., Ozpolat B., Ittmann M.M. Highly specific targeting of the TMPRSS2/ERG fusion gene using liposomal nanovectors. Clin. Cancer Res. 2012, 18(24):6648-6657.
73. Merritt W.M., Lin Y.G., Spannuth W.A., Fletcher M.S., Kamat A.A., Han L.Y., Landen C.N., Jennings N., De Geest K., Langley R.R., Villares G., Sanguino A., Lutgendorf S.K., Lopez-Berestein G., Bar-Eli M.M., Sood A.K. Effect of interleukin-8 gene silencing with liposome-encapsulated small interfering RNA on ovarian cancer cell growth. J. Natl. Cancer Inst. 2008, 100:359-372.
74. Tekedereli I., Alpay S.N., Akar U., Yuca E., Aguayo-Rodriguez C., Han H.D., Sood A.K., Lopez-Berestein G., Ozpolat B. Therapeutic silencing of Bcl-2 by systemically administered siRNA nanotherapeutics inhibits tumor growth by autophagy and apoptosis and enhances the efficacy of chemotherapy in orthotopic xenograft models of ER (-) and ER (+) breast cancer. Mol. Ther.-Nucleic Acids 2013, 2:e121.
75. Zimmermann T.S., Lee A.C., Akinc A., Bramlage B., Bumcrot D., Fedoruk M.N., Harborth J., Heyes J.A., Jeffs L.B., John M., Judge A.D., Lam K., McClintock K., Nechev L.V., Palmer L.R., Racie T., Röhl I., Seiffert S., Shanmugam S., Sood V., Soutschek J., Toudjarska I., Wheat A.J., Yaworski E., Zedalis W., Koteliansky V., Manoharan M., Vornlocher H.P., MacLachlan I. RNAi-mediated gene silencing in non-human primates. Nature 2006, 441:111-114.
76. Kim H.R., Kim I.K., Bae K.H., Lee S.H., Lee Y., Park T.G. Cationic solid lipid nanoparticles reconstituted from low density lipoprotein components for delivery of siRNA. Mol. Pharm. 2008, 5:622-631.
77. Akinc A., Zumbuehl A., Goldberg M., et al. A combinatorial library of lipid-like materials for delivery of RNAi therapeutics. Nat. Biotechnol. 2008, 26(5):561-569.
78. Wolfrum C., Shi S., Jayaprakash K.N., et al. Mechanisms and optimization of in vivo delivery of lipophilic siRNAs. Nat. Biotechnol. 2007, 25:1149-1157.
79. Villares G.J., Zigler M., Wang H., et al. Targeting melanoma growth and metastasis with systemic delivery of liposome-incorporated protease-activated receptor-1 small interfering RNA. Cancer Res. 2008, 68:9078-9086.
80. Klein S., Zolk O., Fromm M.F., Schrödl F., Neuhuber W., Kryschi C. Functionalized silicon quantum dots tailored for targeted siRNA delivery. Biochem Biophys Res Commun. 2009, 387(1):164-168.
81. Derfus A.M., Chen A.A., Min D.H., Ruoslahti E., Bhatia S.N. Targeted quantum dot conjugates for siRNA delivery. Bioconjug. Chem. 2007, 18(5):1391-1396.
82. Burnett J.C., Rossi J.J., Tiemann K. Current progress of siRNA/shRNA therapeutics in clinical trials. Biotechnol. J. 2011, 6(9):1130-1146.
83. Burnett J.C., Rossi J.J. RNA-based therapeutics: current progress and future prospects. Chem. Biol. 2012, 19(1):60-71.
84. Kaiser P.K., Symons R.C., Shah S.M., Quinlan E.J., Tabandeh H., Do D.V., Reisen G., Lockridge J.A., Short B., Guerciolini R., Nguyen Q.D., Sirna-027 Study Investigators RNAi-based treatment for neovascular age-related macular degeneration by Sirna-027. Am J. Ophthalmol. 2010, 150(1):33-39.
85. Nguyen Q.D., Schachar R.A., Nduaka C.I., Sperling M., Basile A.S., Klamerus K.J., Chi-Burris K., Yan E., Paggiarino D.A., Rosenblatt I., Khan A., Aitchison R., Erlich S.S., PF-04523655 Study Group Phase 1 dose-escalation study of a siRNA targeting the RTP801 gene in age-related macular degeneration patients. Eye (Lond.) 2012, 26(8):1099-1105.
86. Zamora M.R., Budev M., Rolfe M., Gottlieb J., Humar A., Devincenzo J., Vaishnaw A., Cehelsky J., Albert G., Nochur S., Gollob J.A., Glanville A.R. RNA interference therapy in lung transplant patients infected with respiratory syncytial virus. Am. J. Respir. Crit. Care Med. 2011, 183(4):531-538.
87. Leachman S.A., Hickerson R.P., Schwartz M.E., Bullough E.E., Hutcherson S.L., Boucher K.M., Hansen C.D., Eliason M.J., Srivatsa G.S., Kornbrust D.J., Smith F.J., McLean W.I., Milstone L.M., Kaspar R.L. First-in-human mutation-targeted siRNA phase Ib trial of an inherited skin disorder. Mol. Ther. 2010, 18(2):442-446.
88. Martínez T., González M.V., Roehl I., Wright N., Pañeda C., Jiménez A.I. In vitro and in vivo efficacy of SYL040012, a novel siRNA compound for treatment of glaucoma. Mol. Ther. 2014, 22(1):81-91.
89. Zorde Khvalevsky E., Gabai R., Rachmut I.H., Horwitz E., Brunschwig Z., Orbach A., Shemi A., Golan T., Domb A.J., Yavin E., Giladi H., Rivkin L., Simerzin A., Eliakim R., Khalaileh A., Hubert A., Lahav M., Kopelman Y., Goldin E., Dancour A., Hants Y., Arbel-Alon S., Abramovitch R., Shemi A., Galun E. Mutant KRAS is a druggable target for pancreatic cancer. Proc. Natl. Acad. Sci. U. S. A. 2013, 110(51):20723-20728.
90. Davis M.E., Zuckerman J.E., Choi C.H.J., Seligson D., Tolcher A., Alabi C.A., Yen Y., Heidel J.D., Ribas A. Evidence of RNAi in humans from systemically administered siRNA via targeted nanoparticles. Nature 2010, 464:1067.
91. Zuckerman J.E., Gritli I., Tolcher A., Heidel J.D., Lim D., Morgan R., Chmielowski B., Ribas A., Davis M.E., Yen Y. Correlating animal and human phase Ia/Ib clinical data with CALAA-01, a targeted, polymer-based nanoparticle containing siRNA. Proc. Natl. Acad. Sci. U. S. A. 2014, 111(31):11449-11454.
92. Strumberg D., Schultheis B., Traugott U., Vank C., Santel A., Keil O., Giese K., Kaufmann J., Drevs J. Phase I clinical development of Atu027, a siRNA formulation targeting PKN3 in patients with advanced solid tumors. Int. J. Clin. Pharmacol. Ther. 2012, 50(1):76-78.
93. Coelho T., Adams D., Silva A., Lozeron P., Hawkins P.N., Mant T., Perez J., Chiesa J., Warrington S., Tranter E., Munisamy M., Falzone R., Harrop J., Cehelsky J., Bettencourt B.R., Geissler M., Butler J.S., Sehgal A., Meyers R.E., Chen Q., Borland T., Hutabarat R.M., Clausen V.A., Alvarez R., Fitzgerald K., Gamba-Vitalo C., Nochur S.V., Vaishnaw A.K., Sah D.W., Gollob J.A., Suhr O.B. Safety and efficacy of RNAi therapy for transthyretin amyloidosis. N. Engl. J. Med. 2013, 369(9):819-829.
94. Fitzgerald K., Frank-Kamenetsky M., Shulga-Morskaya S., Liebow A., Bettencourt B.R., Sutherland J.E., Hutabarat R.M., Clausen V.A., Karsten V., Cehelsky J., Nochur S.V., Kotelianski V., Horton J., Mant T., Chiesa J., Ritter J., Munisamy M., Vaishnaw A.K., Gollob J.A., Simon A. Effect of an RNA interference drug on the synthesis of proprotein convertase subtilisin/kexin type 9 (PCSK9) and the concentration of serum LDL cholesterol in healthy volunteers: a randomised, single-blind, placebo-controlled, phase 1 trial. Lancet 2014, 383(9911):60-68.
95. Heidel J.D., Yu Z., Liu J.Y., Rele S.M., Liang Y., Zeidan R.K., Kornbrust D.J., Davis M.E. Administration in non-human primates of escalating intravenous doses of targeted nanoparticles containing ribonucleotide reductase subunit M2 siRNA. Proc. Natl. Acad. Sci. U. S. A. 2007, 104:5715-5721.
96. Flenniken A.M., Gale N.W., Yancopoulos G.D., Wilkinson D.G. Distinct and overlapping expression patterns of ligands for Eph-related receptor tyrosine kinases during mouse embryogenesis. Dev. Biol. 1996, 179:382-401.
97. Lindberg R.A., Hunter T. cDNA cloning and characterization of eck, an epithelial cell receptor protein-tyrosine kinase in the eph/elk family of protein kinases. Mol. Cell. Biol. 1990, 10(12):6316-6324.
98. Zelinski D.P., Zantek N.D., Stewart J.C., Irizarry A.R., Kinch M.S. EphA2 overexpression causes tumorigenesis of mammary epithelial cells. Cancer Res. 2001, 61(5):2301-2306.
99. Walker-Daniels J., Coffman K., Azimi M., Rhim J.S., Bostwick D.G., Snyder P., Kerns B.J., Waters D.J., Kinch M.S. Overexpression of the EphA2 tyrosine kinase in prostate cancer. Prostate 1999, 41:275-280.
100. Easty D.J., Bennett D.C. Protein tyrosine kinases in malignant melanoma. Melanoma Res. 2000, 10(5):401-411.
101. Nemoto T., Ohashi K., Akashi T., Johnson J.D., Hirokawa K. Overexpression of protein tyrosine kinases in human esophageal cancer. Pathobiology 1997, 65:195-203.
102. Kinch M.S., Moore M.B., Harpole D.H. Predictive value of the EphA2 receptor tyrosine kinase in lung cancer recurrence and survival. Clin. Cancer Res. 2003, 9(2):613-618.
103. Hess A.R., Seftor E.A., Gardner L.M., Carles-Kinch K., Schneider G.B., Seftor R.E., Kinch M.S., Hendrix M.J. Molecular regulation of tumor cell vasculogenic mimicry by tyrosine phosphorylation: role of epithelial cell kinase (Eck/EphA2). Cancer Res. 2001, 61(8):3250-3255.
104. Siegel R., Ma J., Zou Z., Jemal A. Cancer statistics. CA Cancer J. Clin. 2014, 64(1):9-29.
105. McGuire W.P., Hoskins W.J., Brady M.F., Kucera P.R., Partridge E.E., Look K.Y., Clarke-Pearson D.L., Davidson M. Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer. N. Engl. J. Med. 1996, 334(1):1-6.
106. du Bois A., Neijt J.P., Thigpen J.T. First line chemotherapy with carboplatin plus paclitaxel in advanced ovarian cancer-a new standard of care?. Ann. Oncol. 1999, 10(Suppl. 1):35-41.
107. Thaker P.H., Deavers M., Celestino J., Thornton A., Fletcher M.S., Landen C.N., Kinch M.S., Kiener P.A., Sood A.K. EphA2 expression is associated with aggressive features in ovarian carcinoma. Clin. Cancer Res. 2004, 10:5145-5150.
108. Han L., Dong Z., Qiao Y., Kristensen G.B., Holm R., Nesland J.M., Suo Z. The clinical significance of EphA2 and Ephrin A-1 in epithelial ovarian carcinomas. Gynecol. Oncol. 2005, 99(2):278-286.
109. Landen C.N., Kinch M.S., Sood A.K. EphA2 as a target for ovarian cancer therapy. Expert Opin. Ther. Targets 2005, 9(6):1179-1187.
110. Lin Y.G., Han L.Y., Kamat A.A., Merritt W.M., Landen C.N., Deavers M.T., Fletcher M.S., Urbauer D.L., Kinch M.S., Sood A.K. EphA2 overexpression is associated with angiogenesis in ovarian cancer. Cancer 2007, 109(2):332-340.
111. Walker-Daniels J., Hess A.R., Hendrix M.J., Kinch M.S. Differential regulation of EphA2 in normal and malignant cells. Am. J. Pathol. 2003, 162(4):1037-1042.
112. Landen C.N., Lu C., Han L.Y., Coffman K.T., Bruckheimer E., Halder J., Mangala L.S., Merritt W.M., Lin Y.G., Gao C., Schmandt R., Kamat A.A., Li Y., Thaker P., Gershenson D.M., Parikh N.U., Gallick G.E., Kinch M.S., Sood A.K. Efficacy and antivascular effects of EphA2 reduction with an agonistic antibody in ovarian cancer. J. Natl. Cancer Inst. 2006, 98(21):1558-1570.
113. Pratt R.L., Kinch M.S. Activation of the EphA2 tyrosine kinase stimulates the MAP/ERK kinase signaling cascade. Oncogene 2002, 21(50):7690-7699.
114. Shen H., Rodriguez-Aguayo C., Xu R., Gonzalez-Villasana V., Mai J., Huang Y., Zhang G., Guo X., Bai L., Qin G., Deng X., Li Q., Erm D.R., Aslan B., Liu X., Sakamoto J., Chavez-Reyes A., Han H.D., Sood A.K., Ferrari M., Lopez-Berestein G. Enhancing chemotherapy response with sustained EphA2 silencing using multistage vector delivery. Clin. Cancer Res. 2013, 19(7):1806-1815.
115. Jiang D., Mangala L.S., Wang H., Wu S., Rao L.G., Rodriguez-Aguayo C., Pradeep S., Volk D.E., Lopez-Berestein G.l, Sood A.K. Tumor vasculature targeting using cell-specific thioaptamer decorated chitosan nanoparticle [abstract]. Cancer Res 2014, 74 74(19 Suppl). AACR, San Diego, CA. Philadelphia (PA), Abstract nr 4468.
116. Han H.D., Mangala L.S., Lee J.W., Shahzad M.M., Kim H.S., Shen D., Nam E.J., Mora E.M., Stone R.L., Lu C. Targeted gene silencing using RGD-labeled chitosan nanoparticles. Clin. Cancer Res. 2010, 16:3910-3922.
117. Tari A., Khodadadian M., Ellerson D., Deisseroth A., Lopez-Berestein G. Liposomal delivery of oligodeoxynucleotides. Leuk. Lymphoma 1996, 21(1-2):93-97.
118. Tari A.M., Andreeff M., Kleine H.D., Lopez-Berestein G. Cellular uptake and localization of liposomal-methylphosphonate oligodeoxynucleotides. J. Mol. Med. (Berl) 1996, 74(10):623-628.
119. Gutiérrez-Puente Y., Tari A.M., Stephens C., Rosenblum M., Guerra R.T., Lopez-Berestein G. Safety, pharmacokinetics, and tissue distribution of liposomal P-ethoxy antisense oligonucleotides targeted to Bcl-2. J. Pharmacol. Exp. Ther. 1999, 291(2):865-869.
120. Tari A.M., Gutiérrez-Puente Y., Monaco G., Stephens C., Sun T., Rosenblum M., Belmont J., Arlinghaus R., Lopez-Berestein G. Liposome-incorporated Grb2 antisense oligodeoxynucleotide increases the survival of mice bearing bcr-abl-positive leukemia xenografts. Int. J. Oncol. 2007, 31(5):1243-1250.
121. Ohanian M., Kantarjian H.M., Ravandi F., Borthakur G., Garcia-Manero G., Andreeff M., Jabbour E., Konopleva M., O'Brien S., Quintas-Cardama A., Somer B.G., Tari A., Verstovsek S., Wierda W.G., Cortes J.E. Safety, pharmacokinetics, and efficacy Of BP-100-1.01 (liposomal Grb-2 antisense oligonucleotide) in patients with refractory or relapsed acute myeloid leukemia (AML). Philadelphia Chromosome Positive Chronic Myelogenous Leukemia (CML), Acute Lymphoblastic Leukemia (ALL), And Myelodysplastic Syndrome (MDS), American Society of Hematology 55th Annual meeting and Exposition, New Orleans LA, December 7-10, 2013, Abstract Nr: 2679 2013.
122. https://clinicaltrials.gov/ct2/show/NCT01591356.